The natural antioxidant and LOX-1 modulating properties of BEO-NVF appear to be promising for use in MetS to decrease endothelial dysfunction, smooth muscle cell proliferation and inflammation, all of which bridge the gap between MetS and ASCVD. Here, OLR1 is linked to atherosclerosis.